Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.
Proton pump inhibitors (PPIs) may be linked to concentration and memory problems in individuals with a history of breast cancer.
Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo and AstraZeneca) is a new treatment option for patients with HER2-positive breast cancer who have progressed after 2 or more prior regimens.
Approximately 1 in 8 women living in the United States will develop an invasive form of breast cancer at some point in her life
First PIK3CA inhibitor treatment approved, along with diagnostic test.
Recent trial shows greater invasive disease-free survival when treated with Kadcyla , (ado-trastuzumab emtansine)
Women no longer require nine months of contraception post cessation of the drug.
Image Credit: Cancer Health
The FDA has extended the indication for breast cancer drug Ibrance (palbociclib) to male patients.
Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma.
Talzenna (talazoparib, Pfizer)
Indications: Adult Patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.